Thomas Baudier

Thomas Baudier

Auto-generated profile, based on publicly available information

Thomas Baudier

Centre Léon Bérard, 28 rue Laennec 69373, LYON Cedex 08, France; CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, Villeurbanne, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
DSDavid Sarrut
David Sarrut
NANicolas Arbor
Nicolas Arbor
TBThomas Baudier
Thomas Baudier
DBDamian Borys
Damian Borys
AEAne Etxebeste
Ane Etxebeste
LMLydia Maigne
Lydia Maigne
This paper reviews the ecosystem of GATE, an open-source Monte Carlo toolkit for medical physics. Based on the shoulders of Geant4, the principal modules (geometry, physics, scorers) are described with brief descriptions of some key concepts (Volume, Actors, Digitizer). The main source code repositories are detailed together with the automated compilation and tests processes (Continuous Integration). We then described how the OpenGATE collaboration managed the collaborative development of about one hundred developers during almost 20 years. The impact of GATE on medical physics and cancer research is then summarized, and examples of a few key applications are given. Finally, future development perspectives are indicated.

6 March 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
DKDavid kryza
David kryza
JWJennifer Wischhusen
Jennifer Wischhusen
MRMathieu Richaud
Mathieu Richaud
MHMaëva Hervieu
Maëva Hervieu
JBJacqueline Sidi Boumedine
Jacqueline Sidi Boumedine
BGBenjamin Gibert
Benjamin Gibert
Targeted radionuclide therapy is a revolutionary tool for the treatment of highly spread metastatic cancers. Most current approaches rely on the use of vectors to deliver radionuclides to tumor cells, targeting membrane‐bound cancer‐specific moieties. Here, we report the embryonic navigation cue netrin‐1 as an unanticipated target for vectorized radiotherapy. While netrin‐1, known to be re‐expressed in tumoral cells to promote cancer progression, is usually characterized as a diffusible ligand, we demonstrate here that netrin‐1 is actually poorly diffusible and bound to the extracellular matrix. A therapeutic anti‐netrin‐1 monoclonal antibody (NP137) has been preclinically developed and was tested in various clinical trials showing an excellent safety profile. In order to provide a companion test detecting netrin‐1 in solid tumors and allowing the selection of therapy‐eligible patients, we used the clinical‐grade NP137 agent and developed an indium‐111‐NODAGA‐NP137 single photon emission computed tomography (SPECT) contrast agent. NP137‐ 111 In provided specific detection of netrin‐1‐positive tumors with an excellent signal‐to‐noise ratio using SPECT/CT imaging in different mouse models. The high specificity and strong affinity of NP137 paved the way for the generation of lutetium‐177‐DOTA‐NP137, a novel vectorized radiotherapy, which specifically accumulated in netrin‐1‐positive tumors. We demonstrate here, using tumor cell‐engrafted mouse models and a genetically engineered mouse model, that a single systemic injection of NP137‐ 177 Lu provides important antitumor effects and prolonged mouse survival. Together, these data support the view that NP137‐ 111 In and NP137‐ 177 Lu may represent original and unexplored imaging and therapeutic tools against advanced solid cancers.

1 December 2017 in Physica Medica
Verified
Journal Article
Closed access
DSDavid Sarrut
David Sarrut
TBThomas Baudier
Thomas Baudier
MAMyriam Ayadi
Myriam Ayadi
RTronan tanguy
ronan tanguy
SRSimon Rit
Simon Rit

18 April 2023 in Physica Medica
Verified
Journal Article
Open access
MAMyriam Ayadi
Myriam Ayadi
PDPauline Dupuis
Pauline Dupuis
TBThomas Baudier
Thomas Baudier
LPLaeticia Padovani
Laeticia Padovani
DSDavid Sarrut
David Sarrut
MSMarie-Pierre Sunyach
Marie-Pierre Sunyach
The reirradiation number increased due to systemic therapies and patient survival. Few guidelines regarding acceptable cumulative doses to organs at risk (OARs) and appropriate dose accumulation tools need, made reirradiation challenging. The survey objective was to present the French current technical and clinical practices in reirradiations. A group of physician and physicists developed a survey gathering major issues of the topic. The questionnaire consisted in 4 parts: data collection, demographic, clinical and technical aspects. It was delivered through the SFRO and the SFPM. Data collection lasted 2 months and were gathered to compute statistical analysis. 48 institutions answered the survey. Difficulties about patient data collection were related to patient safety, administrative and technical limitations. Half of the institutions discussed reirradiation cases during a multidisciplinary meeting. It mainly aimed at discussing the indication and the new treatment total dose (92%). 79% of the respondents used various references but only 6% of them were specific to reirradiations. Patients with pain and clinical deficit were ranked as best inclusion criteria. 54.2% of the institutions considered OARs recovery, especially for spinal cord and brainstem. A commercial software was used for dose accumulation for 52% of respondents. Almost all institutions performed equivalent dose conversion (94%). A quarter of the institutions estimated not to have the appropriate equipment for reirradiation. This survey showed the various approaches and tools used in reirradiation management. It highlighted issues in collecting data, and the guidelines necessity for safe practices, to increase clinicians confidence in retreating patients.

10 January 2024 in Physica Medica
Verified
Journal Article
Closed access
FFFrancesca di Franco
Francesca di Franco
TBThomas Baudier
Thomas Baudier
PPPierre Marie Pialat
Pierre Marie Pialat
AMAlexandre Munoz
Alexandre Munoz
MMMurielle Martinon
Murielle Martinon
MBMarie-Claude Biston
Marie-Claude Biston

23 December 2021 in IEEE Transactions on Radiation and Plasma Medical Sciences
Verified
Journal Article
Closed access
ARAntoine Robert
Antoine Robert
SRSimon Rit
Simon Rit
TBThomas Baudier
Thomas Baudier
JJJulien Jomier
Julien Jomier
DSDavid Sarrut
David Sarrut
Respiratory motion leads to blur and artifacts in single-photon emission computed tomography (SPECT) images. This may be an issue in some treatments such as liver radioembolization. The purpose of this work was to reconstruct 4-D respiration-gated SPECT images using a data-driven approach. A respiratory signal was extracted from SPECT list-mode data using Laplacian eigenmaps and used for retrospective phase gating. The method was evaluated on various SPECT datasets: Monte Carlo simulation of a patient acquisition, several acquisitions of a dynamic phantom, and 20 acquisitions of patients treated with liver radioembolization. We observed an increase of the mean activity inside the tumor (A) and of the tumor-to-normal liver ratio (T/N) in the respiration-gated SPECT image compared to the 3-D image without motion correction. For the patient acquisitions, an average 3.3% (up to 11.9%) and 3.2% (up to 9.7%) increase was observed for A and T/N, respectively. For the simulation, the activity was within 2.6% of the reference without movement and around 3% for the three patterns of tumor motion simulated with the mechanical phantom. Overall, the proposed respiration-gated SPECT reconstruction improves the estimation of the activity in the tumor without the need for extra hardware.